Reading, not marketing.

Our medical team publishes articles, research summaries, and patient guides. Everything is written in-house. Nothing is gated. If you find something useful, that’s the goal — whether or not you ever become a patient.

Foundations · Featured

What peptides actually are — and what they aren’t.

The term gets thrown around like a synonym for steroids, supplements, and hormones. It isn’t. A working definition you can trust — plus the categorical distinctions most articles skip.

Read article

Recent Articles
Regulatory

FDA-approved vs. compounded vs. research peptides

The category most patients get wrong. An honest guide to what’s legal to prescribe, what’s prescribed off-label, and what’s research-only.

Read article
Myth vs. Evidence

BPC-157: what the research does and doesn’t show

Preclinical data is genuinely encouraging. Human data is thinner than most clinics will admit. Both sides, without the spin.

Read article
Patient Guide

What to expect in your first 90 days on a GLP-1

Titration, side effects, labs, and the honest timeline for meaningful weight change. A walkthrough, not a sales pitch.

Read article
Research Summary

Tirzepatide at 72 weeks: reviewing the SURMOUNT data

A clinical read of the SURMOUNT-1 through -4 trials, what the data actually says, and what remains uncertain about long-term use.

Read article
Foundations

Why compounding matters (and when it doesn’t)

A plain-language explanation of 503A and 503B compounding, why sourcing is everything, and how to evaluate a pharmacy.

Read article
Myth vs. Evidence

Growth hormone peptides and “anti-aging”

GHRH/GHRP peptides do raise endogenous GH. They do not reverse aging. A clear-eyed look at the difference.

Read article
Patient Guide

Preparing for your peptide consultation

A checklist of the labs, history, and medications to gather before your first visit so we can make the most of your time.

Read article
Research Summary

Thymosin alpha-1: reviewing 30 years of international data

Approved in over 30 countries outside the U.S., thymosin alpha-1 has a surprisingly robust evidence base. A tour through it.

Read article
Regulatory

The 2024 compounding landscape explained

FDA guidance has evolved. Here’s what changed, what it means for patients, and how we adapted our formulary.

Read article
Newsletter

A monthly dispatch, no hype.

One email a month from our medical team with new research summaries, regulatory updates, and deep-dives. You can unsubscribe in one click.